A

Agenus
D

AGEN

5.94500
USD
-0.11
(-1.82%)
مغلق
حجم التداول
30,025
الربح لكل سهم
2
العائد الربحي
-
P/E
0
حجم السوق
162,993,173
أصول ذات صلة
A
ADVM
0.03000
(1.12%)
2.71000 USD
A
APPS
0.08000
(1.48%)
5.47500 USD
A
ARDX
-0.07500
(-1.72%)
4.28500 USD
A
ASC
-0.065
(-0.63%)
10.215 USD
A
ATRA
-0.440
(-3.61%)
11.760 USD
A
AVXL
-0.635
(-4.98%)
12.125 USD
N
NERV
0.16000
(8.08%)
2.14000 USD
A
AIM
-0.31000
(-3.63%)
8.24000 USD
المزيد
الأخبار المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).